Developments and strategies for inhaled antibiotic drugs in tuberculosis therapy: A critical evaluation

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 86, Issue 1, 2014, Pages 23-30

  Hoppentocht, M ^a   Hagedoorn, P ^a   Frijlink, H W ^a   De Boer, A H ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Antibiotics; Dry powder inhalers; Inhaled antibiotics; Pulmonary administration; Pulmonary infections; Tuberculosis

Indexed keywords

ANTIBIOTIC AGENT; ETHAMBUTOL; EXCIPIENT; ISONIAZID; ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; PYRAZINAMIDE; RIFAMPICIN; TOBRAMYCIN;

AEROSOL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; DEVELOPING COUNTRY; DRUG EFFICACY; DRUG SAFETY; DRY POWDER; HUMAN; INHALATION; INHALER; MYOFIBROBLAST; PHAGOCYTE; PHYSICAL CHEMISTRY; PHYSIOLOGICAL PROCESS; PREVALENCE; REVIEW; TUBERCULOSIS;

ANTIBIOTICS; DRY POWDER INHALERS; INHALED ANTIBIOTICS; PULMONARY ADMINISTRATION; PULMONARY INFECTIONS; TUBERCULOSIS;

ADMINISTRATION, INHALATION; ANTIBIOTICS, ANTITUBERCULAR; CHEMISTRY, PHARMACEUTICAL; DISEASE TRANSMISSION, INFECTIOUS; DRUG DISCOVERY; DRY POWDER INHALERS; HUMANS; PHAGOCYTES; PULMONARY ALVEOLI; TUBERCULOSIS, PULMONARY;

EID: 84896697704     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2013.10.019     Document Type: Review

References (78)

1. H. Heijerman, E. Westerman, S. Conway, and D. Touw Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus J. Cyst. Fibros. 8 2009 295 315
2. D. Traini, and P.M. Young Delivery of antibiotics to the respiratory tract: an update Expert Opin. Drug Deliv. 6 2009 897 905
3. P. Muttil, C. Wang, and A. Hickey Inhaled drug delivery for tuberculosis therapy Pharm. Res. 26 2009 2401 2416
4. M. Karvouniaris, D. Makris, A. Triantaris, and E. Zakynthinos Inhaled antibiotics for nosocomial pneumonia Inflamm. Allergy Drug Targets 11 2012 116 123
5. J.S. Patton, and P.R. Byron Inhaling medicines: delivering drugs to the body through the lungs Nat. Rev. Drug Discov. 6 2007 67 74
6. G. Döring, and N. Hoiby Early intervention and prevention of lung disease in cystic fibrosis: a European consensus J. Cyst. Fibros. 3 2004 67 91
7. B.W. Ramsey, M.S. Pepe, J.M. Quan, K.L. Otto, A.B. Montgomery, J. Williams-Warren, M. Vasiljev-K, D. Borowitz, C.M. Bowman, B.C. Marshall, S. Marshall, and A.L. Smith Intermittent administration of inhaled tobramycin in patients with cystic fibrosis N. Engl. J. Med. 340 1999 23 30
8. R.B. Moss Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis Chest 121 2002 55 63
9. T.D. Murphy, R.D. Anbar, L.A. Lester, S.Z. Nasr, B. Nickerson, D.R. VanDevanter, and A.A. Colin Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease Pediatr. Pulm. 38 2004 314 320
10. S. Vassal, R. Taamma, N. Marty, A. Sardet, P. d'Athis, F. Brémont, M.L. Dalphin, P. Plésiat, G. Rault, J. Thubert, S. Dominique, J.F. Lemeland, J. Derelle, M.F. Blech, M. Roussey, M. Perrin, and A. Sautegeau Microbiologic contamination study of nebulizers after aerosol therapy in patients with cystic fibrosis Am. J. Infect. Control 28 2000 347 351
11. Leonard V. Sacks, S. Pendle, D. Orlovic, M. Andre, M. Popara, G. Moore, L. Thonell, and S. Hurwitz Adjunctive salvage therapy with inhaled aminoglycosides for patients with persistent smear-positive pulmonary tuberculosis Clin. Infect. Dis. 32 2001 44 49
12. A. Misra, A.J. Hickey, C. Rossi, G. Borchard, H. Terada, K. Makino, P.B. Fourie, and P. Colombo Inhaled drug therapy for treatment of tuberculosis Tuberculosis 91 2011 71 81
13. M. Lauzardo, and C.A. Peloquin Antituberculosis therapy for 2012 and beyond Expert. Opin. Pharmacother. 13 2012 2012 511 526
14. J.H. Grosset, T.G. Singer, and W.R. Bishai New drugs for the treatment of tuberculosis: hope and reality Int. J. Tuberc. Lung Dis. 16 2012 1005 1014
15. WHO, Treatment of Tuberculosis Guidelines, 2010.
16. M.-P. Mingeot-Leclercq, Y. Glupczynski, and P.M. Tulkens Aminoglycosides: activity and resistance Antimicrob. Agents Chemother. 43 1999 727 737
17. L. Heifets, J. Simon, and V. Pham Capreomycin is active against non-replicating M. tuberculosis Ann. Clin. Microbiol. Antimicrob. 4 2005 6
18. A.S. Ginsburg, J.H. Grosset, and W.R. Bishai Fluoroquinolones, tuberculosis, and resistance Lancet Infect. Dis. 3 2003 432 442
19. E.L. Nuermberger, T. Yoshimatsu, S. Tyagi, R.J. O'Brien, A.N. Vernon, R.E. Chaisson, W.R. Bishai, and J.H. Grosset Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis Am. J. Respir. Crit. Care Med. 169 2004 421 426
20. M. Ballmann, A. Smyth, and D.E. Geller Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics Respir. Med. 105 Suppl. 2 2011 S2 S8
21. D. Touw, R. Brimicombe, M. Hodson, H. Heijerman, and W. Bakker Inhalation of antibiotics in cystic fibrosis Eur. Respir. J. 8 1995 1594 1604
22. J.M. Littlewood, M.G. Miller, A.T. Ghoneim, and C.H. Ramsden Nebulised colomycin for early Pseudomonas colonisation in cystic fibrosis Lancet 325 1985 865
23. J. Hung, G. Hambleton, and M. Super Evaluation of two commercial jet nebulisers and three compressors for the nebulisation of antibiotics Arch. Dis. Child. 71 1994 335 338
24. D.E. Geller, and S. Madge Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosis Respir. Med. 105 Suppl. 2 2011 S24 S31
25. P. Greally, P. Whitaker, and D. Peckham Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis Curr. Med. Res. Opin. 28 2012 1059 1067
26. J. Goldman, S. Bayston, S. O'Connor, and R. Meigh Inhaled micronised gentamicin powder: a new delivery system Thorax 45 1990 939 940
27. N. Renee Crowther Labiris, A.M. Holbrook, H. Chrystin, S.M. MacLeod, and M.T. Newhouse Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis. A pilot study Am. J. Respir. Crit. Care Med. 160 1999 1711 1716
28. F.Q. Li, J.H. Hu, B. Lu, H. Yao, and W.G. Zhang Ciprofloxacin-loaded bovine serum albumin microspheres: preparation and drug-release in vitro J. Microencapsul. 18 2001 825 829
29. M.M. Arnold, E.M. Gorman, L.J. Schieber, E.J. Munson, and C. Berkland NanoCipro encapsulation in monodisperse large porous PLGA microparticles J. Control. Release 121 2007 100 109
30. T. Mizoe, T. Ozeki, and H. Okada Application of a four-fluid nozzle spray drier to prepare inhalable rifampicin-containing mannitol microparticles AAPS PharmSciTech 9 2008 755 761
31. N. Changsan, H.-K. Chan, F. Separovic, and T. Srichana Physicochemical characterization and stability of rifampicin liposome dry powder formulations for inhalation J. Pharm. Sci. 98 2009 628 639
32. J. Fiegel, L. Garcia-Contreras, M. Thomas, J. VerBerkmoes, K. Elbert, A. Hickey, and D. Edwards Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin Pharm. Res. 25 2008 805 811
33. H. Adi, P.M. Young, H.-K. Chan, R. Salama, and D. Traini Controlled release antibiotics for dry powder lung delivery Drug Dev. Ind. Pharm. 36 2010 119 126
34. M. Tsifansky, Y. Yeo, O. Evgenov, E. Bellas, J. Benjamin, and D. Kohane Microparticles for inhalational delivery of antipseudomonal antibiotics AAPS J. 10 2008 254 260
35. Y. Yang, M. Tsifansky, C.-J. Wu, H.I. Yang, G. Schmidt, and Y. Yeo Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis Pharm. Res. 27 2010 151 160
36. T.R. Desai, R.E.W. Hancock, and W.H. Finlay Delivery of liposomes in dry powder form: aerodynamic dispersion properties Eur. J. Pharm. Sci. 20 2003 459 467
37. A. Schoubben, P. Blasi, S. Giovagnoli, M. Ricci, and C. Rossi Simple and scalable method for peptide inhalable powder production Eur. J. Pharm. Sci. 39 2010 53 58
38. M. Zhao, Y. You, Y. Ren, Y. Zhang, and X. Tang Formulation, characteristics and aerosolization performance of azithromycin DPI prepared by spray-drying Powder Technol. 187 2008 214 221
39. A.K. Dash, and R. Suryanarayanan Solid-state properties of tobramycin Pharm. Res. 8 1991 1159 1165
40. C. Parlati, P. Colombo, F. Buttini, P. Young, H. Adi, A. Ammit, and D. Traini Pulmonary spray dried powders of tobramycin containing sodium stearate to improve aerosolization efficiency Pharm. Res. 26 2009 1084 1092
41. J. Meers Dispersible powders for inhalation applications Innov. Pharm. Tech. 1 2000 111 116
42. S. Ahmad Pathogenesis, immunology, and diagnosis of latent Mycobacterium tuberculosis infection Clin. Dev. Immunol. 2011 17 2011
43. R. Pandey, and G.K. Khuller Antitubercular inhaled therapy: opportunities, progress and challenges J. Antimicrob. Chemother. 55 2005 430 435
44. S. Ramón-García, C. Ng, H. Anderson, J.D. Chao, X. Zheng, T. Pfeifer, Y. Av-Gay, M. Roberge, and C.J. Thompson Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen Antimicrob. Agents Chemother. 55 2011 3861 3869
45. E.A. Nardell, A. Stoltz, A. Dharmadhikari, E.d. Kock, M. Mphahlele, M. Hoppentocht, A.d. Boer, E. Frijlink, K. Venter, M.v.d. Walt, Inhaled colistin: a novel approach for reducing drug-resistant TB transmission, Poster, International Union Against Tuberculosis and Lung Disease, Vancouver, 2013.
46. P.P.H. Le Brun, A.H. de Boer, G.P.M. Mannes, D.M.I. de Fraîture, R.W. Brimicombe, D.J. Touw, A.A. Vinks, H.W. Frijlink, and H.G.M. Heijerman Dry powder inhalation of antibiotics in cystic fibrosis therapy: Part 2: inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients Eur. J. Pharm. Biopharm. 54 2002 25 32
47. E.M. Westerman, P.P.H. Le Brun, D.J. Touw, H.W. Frijlink, and H.G.M. Heijerman Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study J. Cyst. Fibros. 3 2004 23 28
48. O.S. Usmani, M.F. Biddiscombe, and P.J. Barnes Regional lung deposition and bronchodilator response as a function of {beta}2-agonist particle size Am. J. Respir. Crit. Care Med. 172 2005 1497 1504
49. T.R. Gerrity, P.S. Lee, F.J. Hass, A. Marinelli, P. Werner, and R.V. Lourenco Calculated deposition of inhaled particles in the airway generations of normal subjects J. Appl. Physiol. 47 1979 867 873
50. S.P. Newman, G.R. Pitcairn, P.H. Hirst, R.E. Bacon, E. O'Keefe, M. Reiners, and R. Hermann Scintigraphic comparison of budesonide deposition from two dry powder inhalers Eur. Respir. J. 16 2000 178 183
51. G.R. Pitcairn, G. Hooper, X. Luria, X. Rivero, and S.P. Newman A scintigraphic study to evaluate the deposition patterns of a novel anti-asthma drug inhaled from the Cyclohaler dry powder inhaler Adv. Drug Deliv. Rev. 26 1997 59 67
52. P. Morrow, and C. Yu Models of aerosol behaviour in airways F. Moren, M. Newhouse, M. Dolovich, Aerosols in Medicine 1985 Elsevier Amsterdam 149 191
53. H.D. Landahl On the removal of air-borne droplets by the human respiratory tract: I. The lung Bull. Math. Biophys. 12 1950 43 56
54. A. Telenti, P. Imboden, F. Marchesi, L. Matter, K. Schopfer, T. Bodmer, D. Lowrie, M.J. Colston, and S. Cole Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis Lancet 341 1993 647 651
55. K. Ohashi, T. Kabasawa, T. Ozeki, and H. Okada One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis J. Control. Release 135 2009 19 24
56. Y. Zhang, and D. Mitchison The curious characteristics of pyrazinamide: a review Int. J. Tuberc. Lung Dis. 7 2003 6 21
57. M.B. Conde, A. Efron, C. Loredo, G.R.M. De Souza, N.P. Graça, M.C. Cezar, M. Ram, M.A. Chaudhary, W.R. Bishai, A.L. Kritski, and R.E. Chaisson Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial Lancet 373 2009 1183 1189
58. R. Sharma, D. Saxena, A.K. Dwivedi, and A. Misra Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis Pharm. Res. 18 2001 1405 1410
59. P. Muttil, J. Kaur, K. Kumar, A.B. Yadav, R. Sharma, and A. Misra Inhalable microparticles containing large payload of anti-tuberculosis drugs Eur. J. Pharm. Sci. 32 2007 140 150
60. J.G.Y. Chan, H.-K. Chan, C.A. Prestidge, J.A. Denman, P.M. Young, and D. Traini A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics Eur. J. Pharm. Biopharm. 2012
61. C.R. Catchpole, J.M. Andrews, N. Brenwald, and R. Wise A reassessment of the in-vitro activity of colistin sulphomethate sodium J. Antimicrob. Chemother. 39 1997 255 260
62. A.J. Wolf, B. Linas, G.J. Trevejo-Nuñez, E. Kincaid, T. Tamura, K. Takatsu, and J.D. Ernst Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo J. Immunol. 179 2007 2509 2519
63. P. O'Hara, and A.J. Hickey Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization Pharm. Res. 17 2000 955 961
64. G. Pilcer, and K. Amighi Formulation strategy and use of excipients in pulmonary drug delivery Int. J. Pharm. 392 2010 1 19
65. R.M. Kottmann, A.A. Kulkarni, K.A. Smolnycki, E. Lyda, T. Dahanayake, R. Salibi, S. Honnons, C. Jones, N.G. Isern, J.Z. Hu, S.D. Nathan, G. Grant, R.P. Phipps, and P.J. Sime Lactic acid is elevated in idiopathic pulmonary fibrosis and induces myofibroblast differentiation via pH-dependent activation of transforming growth factor-β Am. J. Respir. Crit. Care Med. 186 2012 740 751
66. P. Byron, and E. Phillips Respiratory Drug Delivery 1990 CRC Press Inc. Florida
67. L.E. Bermudez, and J. Goodman Mycobacterium tuberculosis invades and replicates within type II alveolar cells Infect. Immun. 64 1996 1400 1406
68. W. Rojanarat, N. Changsan, E. Tawithong, S. Pinsuwan, H.-K. Chan, and T. Srichana Isoniazid proliposome powders for inhalation - preparation, characterization and cell culture studies Int. J. Mol. Sci. 12 2011 4414 4434
69. W. Rojanarat, T. Nakpheng, E. Thawithong, N. Yanyium, and T. Srichana Inhaled pyrazinamide proliposome for targeting alveolar macrophages Drug Deliv. 19 2012 334 345
70. Diagnostic standards and classification of tuberculosis in adults and children: this official statement of the American thoracic society and the centers for disease control and prevention was adopted by the ATS board of directors, July 1999. This statement was endorsed by the council of the infectious disease society of America, September 1999, Am. J. Respir. Crit. Care Med. 161 (2000) 1376-1395.
71. G. Friedland, G.J. Churchyard, and E. Nardell Tuberculosis and HIV coinfection: current state of knowledge and research priorities J. Infect. Dis. 196 2007 S1 S3
72. P. Nunn, A. Reid, and K.M. De Cock Tuberculosis and HIV infection: the global setting J. Infect. Dis. 196 2007 S5 S14
73. P.P.H. Le Brun, A.H. de Boer, H.W. Frijlink, and H.G.M. Heijerman A review of the technical aspects of drug nebulization Pharm. World Sci. 22 2000 75 81
74. A.H. de Boer, P. Hagedoorn, E.M. Westerman, P.P.H. Le Brun, H.G.M. Heijerman, and H.W. Frijlink Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer®) for high powder doses Eur. J. Pharm. Sci. 28 2006 171 178
75. P. Le Brun, R. Brimicombe, H. van Doorne, and H. Heijerman The cleaning and disinfection of nebulizers used at home and in a cystic fibrosis centre Eur. Hosp. Pharm. 6 2000 58 63
76. M.B. Dolovich, and R. Dhand Aerosol drug delivery: developments in device design and clinical use Lancet 377 2011 1032 1045
77. C. Friebel, and H. Steckel Single-use disposable dry powder inhalers for pulmonary drug delivery Expert Opin. Drug Deliv. 7 2010 1359 1372
78. D.R. VanDevanter, M. Ballmann, and P.A. Flume Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis Respir. Med. 105 Suppl. 2 2011 S18 S23